Technological watch

Fuller Company expands portfolio with acquisition of Adhezion Biomedical

Fuller Company has acquired Adhezion Biomedical, a US medical adhesives company with customers in more than 40 countries. 

× The acquisition of Adhezion ? which manufactures and distributes highly differentiated, proprietary cyanoacrylate technologies for surgical care, wound management, and infection prevention in healthcare settings ? builds a platform of scale for H.B. Fuller in the topical skin bonding market, adding to capabilities attained from the company’s purchase of Tissue Seal in 2021 and providing vertically integrated adhesive manufacturing and packaging capability. The acquisition decisively positions H.B. Fuller for expansion in the medical adhesives industry and creates a solid, unique platform from which to scale and innovate in the healthcare adhesives space.

Jim East, executive vice president, Hygiene, Health, and Consumable Adhesives, said: “This is a strategic move in support of our long-term growth strategy. H.B. Fuller products have been used around the world in medical applications for more than two decades, enabling new ideas and accelerating innovation. With our acquisition of Adhezion Biomedical, we will not only open new markets and diversify our portfolio, we will significantly strengthen our capabilities in the medical adhesives space, representing a milestone in our commitment to deliver greater value to our customers around the world.”

With a team of approximately 50 employees, Adhezion Biomedical will operate within H.B. Fuller’s existing Hygiene, Health, and Consumable Adhesives global business unit to accelerate growth with new medical grade technology, in-depth application expertise, and reinforced ability to certify new innovations in the healthcare industry around the world.

Back to Search Results Tags Adhesives acquisition Adhezion Biomedical Fuller Company

Publication date: 12/07/2023

Medical Plastics News


This project has received funding from the Bio Based Industries Joint Undertaking under the European Union’s Horizon 2020 research and innovation programme under grant agreement No 837761.